These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 8648102)
1. In vivo T cell response to viral superantigen. Selective migration rather than proliferation. Le Bon A; Lucas B; Vasseur F; Penit C; Papiernik M J Immunol; 1996 Jun; 156(12):4602-8. PubMed ID: 8648102 [TBL] [Abstract][Full Text] [Related]
2. T cell deletion induced by chronic infection with mouse mammary tumor virus spares a CD25-positive, IL-10-producing T cell population with infectious capacity. Papiernik M; do Carmo Leite-de-MoraesM ; Pontoux C; Joret AM; Rocha B; Penit C; Dy M J Immunol; 1997 May; 158(10):4642-53. PubMed ID: 9144476 [TBL] [Abstract][Full Text] [Related]
3. Transfer of endogenous retroviral superantigen from donor to recipient B cells following priming to induce peripheral T cell tolerance. Modlin CS; Todd GT; Cohen TD; Fairchild RL Cell Immunol; 1995 Sep; 164(2):217-26. PubMed ID: 7656330 [TBL] [Abstract][Full Text] [Related]
4. New infectious mammary tumor virus superantigen with V beta-specificity identical to staphylococcal enterotoxin B (SEB). Luther S; Shakhov AN; Xenarios I; Haga S; Imai S; Acha-Orbea H Eur J Immunol; 1994 Aug; 24(8):1757-64. PubMed ID: 8056034 [TBL] [Abstract][Full Text] [Related]
5. Dramatic hyperplasia of mtv-2+ lymph node grafts in mtv-2- recipients and selective stimulation of V beta 14+ T cells in recipients' lymph nodes in the DDD mouse. Matsuzawa A; Nakano H; Sakamoto S; Yoshimoto T; Nariuchi H J Immunol; 1995 Feb; 154(4):1644-52. PubMed ID: 7836749 [TBL] [Abstract][Full Text] [Related]
6. Association of a V beta 2-specific superantigen with a tumorigenic milk-borne mouse mammary tumor virus. Hodes RJ; Novick MB; Palmer LD; Knepper JE J Immunol; 1993 Feb; 150(4):1422-8. PubMed ID: 8094408 [TBL] [Abstract][Full Text] [Related]
7. Early neutralizing antibody response against mouse mammary tumor virus: critical role of viral infection and superantigen-reactive T cells. Luther SA; Maillard I; Luthi F; Scarpellino L; Diggelmann H; Acha-Orbea H J Immunol; 1997 Sep; 159(6):2807-14. PubMed ID: 9300703 [TBL] [Abstract][Full Text] [Related]
8. Recipient polyclonal B cell activation and immunoglobulin production induced by priming with a retroviral superantigen. Modlin CS; Muruve NA; Stanko D; Caulfield MJ; Fairchild RL Cell Immunol; 1996 May; 169(2):252-63. PubMed ID: 8620553 [TBL] [Abstract][Full Text] [Related]
9. Identification of key amino acids of the mouse mammary tumor virus superantigen involved in the specific interaction with T-cell receptor V(beta) domains. Baribaud F; Wirth S; Maillard I; Valsesia S; Acha-Orbea H; Diggelmann H J Virol; 2001 Aug; 75(16):7453-61. PubMed ID: 11462017 [TBL] [Abstract][Full Text] [Related]
10. Activation of natural killer cells by mouse mammary tumor virus C4 in BALB/c and T-cell receptor V beta 2-transgenic mice. Gill R; Wang H; Bluethmann H; Iglesias A; Wei WZ Cancer Res; 1994 Mar; 54(6):1529-35. PubMed ID: 8137259 [TBL] [Abstract][Full Text] [Related]
11. T cells bearing Vbeta8 are preferentially infected with exogenous mouse mammary tumor virus. Upragarin N; Nishimura H; Wajjwalku W; Ando Y; Nagafuchi S; Watanabe T; Yoshikai Y J Immunol; 1997 Sep; 159(5):2189-95. PubMed ID: 9278306 [TBL] [Abstract][Full Text] [Related]
12. Deletion of CD4+ T cells by mouse mammary tumor virus (FM) superantigen with broad specificity of T cell receptor beta-chain variable region. Yoshimoto T; Nagase H; Nakano H; Matsuzawa A; Nariuchi H Virology; 1996 Sep; 223(2):387-91. PubMed ID: 8806576 [TBL] [Abstract][Full Text] [Related]
13. A V beta 8.2-specific superantigen from exogenous mouse mammary tumor virus carried by FM mice. Yoshimoto T; Nagase H; Nakano H; Matsuzawa A; Nariuchi H Eur J Immunol; 1994 Jul; 24(7):1612-9. PubMed ID: 7913038 [TBL] [Abstract][Full Text] [Related]
14. CD28/CTLA4-B7 interaction is dispensable for T cell stimulation by mouse mammary tumor virus superantigen but not for B cell differentiation and virus dissemination. Champagne E; Scarpellino L; Lane P; Acha-Orbea H Eur J Immunol; 1996 Jul; 26(7):1595-602. PubMed ID: 8766566 [TBL] [Abstract][Full Text] [Related]
15. The phenotype and survival of antigen-stimulated transgenic CD4 T cells in vivo: the influence of persisting antigen. Yang CP; Sparshott SM; Duffy D; Garside P; Bell EB Int Immunol; 2006 Apr; 18(4):515-23. PubMed ID: 16481344 [TBL] [Abstract][Full Text] [Related]
16. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells. Inoue M; Plautz GE; Shu S Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987 [TBL] [Abstract][Full Text] [Related]
17. Vbeta-restricted T cell adherence to endothelial cells: a mechanism for superantigen-dependent vascular injury. Brogan PA; Shah V; Klein N; Dillon MJ Arthritis Rheum; 2004 Feb; 50(2):589-97. PubMed ID: 14872503 [TBL] [Abstract][Full Text] [Related]
18. Nonspecific augmentation of lymph node T cells and I-E-independent selective deletion of V beta 14+ T cells by Mtv-2 in the DDD mouse. Nakano H; Yoshimoto T; Kakiuchi T; Matsuzawa A Eur J Immunol; 1993 Oct; 23(10):2434-9. PubMed ID: 8405042 [TBL] [Abstract][Full Text] [Related]
19. Deletion of peripheral V beta 14+ T cells by Mtv-2-encoded viral superantigen preceded by blastogenesis and DNA synthesis but not by specific expansion. Nakano H; Yoshimoto T; Nariuchi H; Kakiuchi T; Matsuzawa A Cell Immunol; 1996 Mar; 168(2):281-90. PubMed ID: 8640876 [TBL] [Abstract][Full Text] [Related]
20. Burn injury induces an early activation response by lymph node CD4+ T cells. Purcell EM; Dolan SM; Kriynovich S; Mannick JA; Lederer JA Shock; 2006 Feb; 25(2):135-40. PubMed ID: 16525351 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]